ADI CEO exercises options, sells 60,000 shares
Analog Devices Chair & CEO Vincent Roche reported an exercise-and-sell sequence involving company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Analog Devices Chair & CEO Vincent Roche reported an exercise-and-sell sequence involving company stock. On May 22, 2026 and May 26, 2026, he exercised stock options covering a total of 60,000 shares of common stock at an exercise price of $144.06 per share and sold 60,000 shares in open-market transactions.
The reported weighted average sale prices ranged from about $396.21 to $416.02 per share across multiple trades. After these transactions, Roche holds 137,537.875 shares of Analog Devices common stock directly, and additional shares are held indirectly through the Vincent Roche 2024 and 2026 Grantor Retained Annuity Trusts, which together report 73,515 shares.
Insider Trade Summary
Exercise and Sale: 60,000 shares ($15.71M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
ROCHE VINCENT
Role
Chair & CEO
Sold
60,000 shs ($24.36M)
Approx. gross sale proceeds
$24.36M
Approx. exercise cost
$8.64M
Approx. pre-tax spread
$15.71M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance-Based Stock Option (right to buy) | 30,000 | $144.06 | $4.32M |
| Exercise | Comm Stock - $.16-2/3 value | 30,000 | $144.06 | $4.32M |
| Sale | Comm Stock - $.16-2/3 value | 20,038 | $414.8255 | $8.31M |
| Sale | Comm Stock - $.16-2/3 value | 9,962 | $415.738 | $4.14M |
| Exercise | Performance-Based Stock Option (right to buy) | 30,000 | $144.06 | $4.32M |
| Exercise | Comm Stock - $.16-2/3 value | 30,000 | $144.06 | $4.32M |
| Sale | Comm Stock - $.16-2/3 value | 29,335 | $396.803 | $11.64M |
| Sale | Comm Stock - $.16-2/3 value | 665 | $397.4956 | $264K |
| holding | Comm Stock-$.16-2/3 value | -- | -- | -- |
| holding | Comm Stock - $.16-2/3 value | -- | -- | -- |
Holdings After Transaction:
Performance-Based Stock Option (right to buy) — 400,000 contracts (Direct);
Comm Stock - $.16-2/3 value — 137,537.875 shares (Direct);
Comm Stock-$.16-2/3 value — 23,515 shares (Indirect, Vincent Roche 2024 Grantor Retained Annuity Trust);
Comm Stock - $.16-2/3 value — 50,000 shares (Indirect, Vincent Roche 2026 Grantor Retained Annuity Trust)
Footnotes (8)
- F1. Excludes 50,000 shares that the Reporting Person previously owned directly, which were contributed to the Vincent Roche 2026 Grantor Retained Annuity Trust.
- F2. These shares were disposed of in multiple transactions at actual sales prices ranging from $396.21 to $397.155 per share. The price reported reflects the weighted average sale price for the transactions. The Reporting Person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. These shares were disposed of in multiple transactions at actual sales prices ranging from $397.31 to $397.54 per share. The price reported reflects the weighted average sale price for the transactions. The Reporting Person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. These shares were disposed of in multiple transactions at actual sales prices ranging from $414.315 to $415.295 per share. The price reported reflects the weighted average sale price for the transactions. The Reporting Person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5. These shares were disposed of in multiple transactions at actual sales prices ranging from $415.335 to $416.020 per share. The price reported reflects the weighted average sale price for the transactions. The Reporting Person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6. Shares held by the Vincent Roche 2024 Grantor Retained Annuity Trust dated October 3, 2024.
- F7. Shares held by the Vincent Roche 2026 Grantor Retained Annuity Trust dated January 11, 2026.
- F8. This option is fully vested.
Key Figures
Shares sold: 60,000 shares
Options exercised: 60,000 shares
Exercise price: $144.06/share
+5 more
8 metrics
Shares sold
60,000 shares
Total open-market sales on May 22 and May 26, 2026
Options exercised
60,000 shares
Performance-based stock options exercised at $144.06 per share
Exercise price
<money>$144.06</money>/share
Exercise price for performance-based stock options
Direct holdings after transactions
137,537.875 shares
Direct Analog Devices common stock held by Roche after trades
2026 GRAT holdings
50,000 shares
Shares held by Vincent Roche 2026 Grantor Retained Annuity Trust
2024 GRAT holdings
23,515 shares
Shares held by Vincent Roche 2024 Grantor Retained Annuity Trust
Option expiration
<date>December 15, 2030</date>
Expiration date of the performance-based stock option series
Reported sale price ranges
<money>$396.21–$416.02</money>/share
Ranges for multiple sale transactions noted in footnotes
Key Terms
Performance-Based Stock Option (right to buy), Grantor Retained Annuity Trust, weighted average sale price, open-market sale, +1 more
5 terms
Performance-Based Stock Option (right to buy) financial
"security title listed as "Performance-Based Stock Option (right to buy)" with 30,000 shares exercised"
Grantor Retained Annuity Trust financial
"shares held by the Vincent Roche 2024 and 2026 Grantor Retained Annuity Trusts are reported as indirect ownership"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
weighted average sale price financial
"footnotes state the price reported reflects the weighted average sale price for multiple transactions"
open-market sale financial
"transaction code S is described as an open-market sale or private transaction in the filing details"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"a footnote notes that the referenced stock option is fully vested"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADI CEO Vincent Roche report in this Form 4?
Vincent Roche reported exercising stock options for 60,000 Analog Devices shares and selling 60,000 shares in open-market transactions on May 22 and May 26, 2026, while retaining a substantial direct and indirect ownership stake.
At what price did ADI’s CEO exercise his stock options?
Roche exercised performance-based stock options for 60,000 underlying shares at an exercise price of $144.06 per share. The options are described as fully vested, with an expiration date of December 15, 2030, in the derivative transaction details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
